Skip to main content
. 2021 Mar 16;11:5962. doi: 10.1038/s41598-021-85270-x

Table 1.

Demographic and clinical characteristics of the studied cohort.

Total Repaired Unrepaired p values
N (%) 49 38 (78%) 11 (22%)
Age (years) 76.1 ± 7.0 76.3 ± 7.0 75.9 ± 8.9 0.89
Sex (M/F) 19/30 17/21 2/9 0.08
Eye (R/L) 23/26 18/20 5/6 0.70
Follow-up (months) 16.3 ± 3.0 16.5 ± 3.2 16.0 ± 2.6 0.63
BCVA (LogMAR)
At RPE tear 0.54 ± 0.27 0.52 ± 0.26 0.62 ± 0.33 0.37
At follow-up 0.66 ± 0.37 0.59 ± 0.32 0.87 ± 0.33 0.04
No. of injections 7.4 ± 3.4 7.4 ± 3.6 7.2 ± 2.9 0.60
SMH at baseline (%) 21 (43%) 16 (42%) 5 (45%) 0.76
Tear onset
Early (%) 33 (67%) 25 (66%) 8 (73%) 0.40
Late (%) 16 (33%) 13 (34%) 3 (27%)
Tear grade
Grade 1 4 (8%) 4 (11%) 0 (0%) 0.93
Grade 2 9 (18%) 7 (18%) 2 (18%)
Grade 3 19 (39%) 13 (34%) 6 (55%)
Grade 4 17 (35%) 14 (37%) 3 (27%)
MNV type
Type 1 (occult) 37 (76%) 30 (79%) 7 (64%) 0.21
Type 2 (classic) 0 (0%) 0 (0%) 0 (0%)
Type 3 (RAP) 12 (24%) 8 (21%) 4 (36%)
Anti-VEGF used
Bevacizumab 15 (31%) 11 4 0.86
Ranibizumab 21 (43%) 17 4
Aflibercept 13 (26%) 10 3

Legend: N, number; BCVA, best-corrected visual acuity; SMH, sub-macular hemorrhage; MNV, macular neovascularization; RAP, retinal angiomatous proliferation; VEGF, vascular endothelial growth factor.